Highlights & Basics
- Type 2 diabetes in children usually presents after the onset of puberty, at a mean age of 14 years, with obesity being the primary cause.
- Often asymptomatic and diagnosed by screening in a high-risk individual (e.g., family history, obesity, acanthosis nigricans) or incidentally (e.g., glycosuria found during a school or sports exam).
- The development of insulin resistance and glucose intolerance can be prevented or delayed by lifestyle modifications that correct obesity in children.
- Goals of treatment are to promote weight loss and exercise capacity, normalize glycemia and hemoglobin A1c (goal is <6.5% [<48 mmol/mol]), and prevent long-term complications and comorbidities (e.g., retinopathy, hypertension, and dyslipidemia).
- Initial treatment includes lifestyle modifications, metformin, and insulin. Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are approved in some countries as an additional non-insulin treatment option for children ages ≥10 years.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Citations
American Diabetes Association. Standards of care in diabetes - 2025. Diabetes care. 2025 Jan;48(suppl 1):S1-352.[Full Text]
Shah AS, Barrientos-Pérez M, Chang N, et al. ISPAD clinical practice consensus guidelines 2024: type 2 diabetes in children and adolescents. Horm Res Paediatr. 2024;97(6):555-83.[Abstract][Full Text]
Glaser N, Fritsch M, Priyambada L, et al. ISPAD clinical practice consensus guidelines 2022: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2022 Nov;23(7):835-56.[Abstract]
1. American Diabetes Association. Standards of care in diabetes - 2025. Diabetes care. 2025 Jan;48(suppl 1):S1-352.[Full Text]
2. Shah AS, Barrientos-Pérez M, Chang N, et al. ISPAD clinical practice consensus guidelines 2024: type 2 diabetes in children and adolescents. Horm Res Paediatr. 2024;97(6):555-83.[Abstract][Full Text]
3. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016 May 27;118(11):1723-35.[Abstract][Full Text]
4. Glaser N, Fritsch M, Priyambada L, et al. ISPAD clinical practice consensus guidelines 2022: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2022 Nov;23(7):835-56.[Abstract]
5. Kaufman FR, Shaw J. Type 2 diabetes in youth: rates, antecedents, treatment, problems and prevention. Pediatr Diabetes. 2007 Dec;8(suppl 9):4-6.[Abstract]
6. Diabetes Australia Guideline Development Consortium. National evidence based guideline for case detection and diagnosis of type 2 diabetes. Jun 2009 [internet publication].[Full Text]
7. Centers for Disease Control and Prevention. National diabetes statistics report: diabetes. May 2024 [internet publication].[Full Text]
8. Misra S, Ke C, Srinivasan S, et al. Current insights and emerging trends in early-onset type 2 diabetes. Lancet Diabetes Endocrinol. 2023 Oct;11(10):768-82.[Abstract]
9. Xie J, Wang M, Long Z, et al. Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019. BMJ. 2022 Dec 7;379:e072385.[Abstract][Full Text]
10. NHS England. Children and young people diabetes toolkit. Jul 2024 [internet publication].[Full Text]
11. Savage PJ, Bennett PH, Senter RG, et al. High prevalence of diabetes in young Pima Indians. Diabetes. 1979 Oct;28(10):937-42.[Abstract]
12. Lascar N, Brown J, Pattison H, et al. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2017 Aug 25;6(1):69-80.[Abstract]
13. Acton KJ, Burrows NR, Moore K, et al. Trends in diabetes prevalence among American Indian and Alaska native children, adolescents, and young adults. Am J Public Health. 2002 Sep;92(9):1485-90.[Abstract][Full Text]
14. Gahagan S, Silverstein J. Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. American Academy of Pediatrics Committee on Native American Child Health. Pediatrics. 2003 Oct;112(4):e328.[Abstract]
15. Lawrence JM, Divers J, Isom S, et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA. 2021 Aug 24;326(8):717-27.[Abstract]
16. Perng W, Conway R, Mayer-Davis E, et al. Youth-onset type 2 diabetes: the epidemiology of an awakening epidemic. Diabetes Care. 2023 Mar 1;46(3):490-9.[Abstract][Full Text]
17. Arslanian S, Bacha F, Grey M, et al. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. Diabetes Care. 2018 Dec;41(12):2648-68.[Full Text]
18. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA. 2008 May 28;299(20):2401-5.[Abstract][Full Text]
19. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005 May;146(5):693-700.[Abstract]
20. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA. 2001 Dec 12;286(22):2845-8.[Abstract][Full Text]
21. Miller J, Rosenbloom A, Silverstein J. Childhood obesity. J Clin Endocrinol Metab. 2004 Sep;89(9):4211-8.[Abstract][Full Text]
22. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011 Jul 9;378(9786):169-81.[Abstract]
23. Ornoy A. Prenatal origin of obesity and its complication: gestational diabetes, maternal overweight and the paradoxical effects of fetal growth restriction and macrosomia. Reprod Toxicol. 2011 Sep;32(2):205-12.[Abstract]
24. Diabetes UK. Type 2 diabetes in children and young people. Aug 2024 [internet publication].[Full Text]
25. Cioana M, Deng J, Nadarajah A, et al. The prevalence of obesity among children with type 2 diabetes: a systematic review and meta-analysis. JAMA Netw Open. 2022 Dec 1;5(12):e2247186.[Abstract][Full Text]
26. Hsueh WA, Quiñones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003 Aug 18;92(4a):10J-7J.[Abstract]
27. Foster GD, Linder B, Baranowski T, et al; HEALTHY Study Group. A school-based intervention for diabetes risk reduction. N Engl J Med. 2010 Jul 29;363(5):443-53.[Abstract][Full Text]
28. Dabelea D, Hanson RL, Lindsay RS, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes. 2000 Dec;49(12):2208-11.[Abstract][Full Text]
29. Ibáñez L, Suárez L, Lopez-Bermejo A, et al. Early development of visceral fat excess after spontaneous catch-up growth in children with low birth weight. J Clin Endocrinol Metab. 2008 Mar;93(3):925-8.[Abstract]
30. Ibáñez L, Ong K, Dunger DB, et al. Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children. J Clin Endocrinol Metab. 2006 Jun;91(6):2153-8.[Abstract]
31. Mericq V, Ong KK, Bazaes R, et al. Longitudinal changes in insulin sensitivity and secretion from birth to age three years in small- and appropriate-for-gestational-age children. Diabetologia. 2005 Dec;48(12):2609-14.[Abstract]
32. Mayer-Davis EJ, Dabelea D, Lamichhane AP, et al. Breast-feeding and type 2 diabetes in the youth of three ethnic groups: the SEARCH for diabetes in youth case-control study. Diabetes Care. 2008 Mar;31(3):470-5.[Abstract][Full Text]
33. Koletzko B. Long-term consequences of early feeding on later obesity risk. Nestle Nutr Workshop Ser Pediatr Program. 2006;58:1-18.[Abstract]
34. Valaiyapathi B, Gower B, Ashraf AP. Pathophysiology of type 2 diabetes in children and adolescents. Curr Diabetes Rev. 2020;16(3):220-9.[Abstract][Full Text]
35. Kelsey MM, Zeitler PS. Insulin resistance of puberty. Curr Diab Rep. 2016 Jul;16(7):64.[Abstract]
36. Arslanian SA. Metabolic differences between Caucasian and African-American children and the relationship to type 2 diabetes mellitus. J Pediatr Endocrinol Metab. 2002 Apr;15 Suppl 1:509-17.[Abstract]
37. Hanis CL, Boerwinkle E, Chakraborty R. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet. 1996 Jun;13(2):161-6.[Abstract]
38. Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011 Jan;96(1):159-67.[Abstract][Full Text]
39. Srinivasan S, Chen L, Todd J, et al. The first genome-wide association study for type 2 diabetes in youth: the progress in diabetes genetics in youth (ProDiGY) Consortium. Diabetes. 2021 Apr;70(4):996-1005.[Abstract][Full Text]
40. Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021 May;137:111315.[Abstract][Full Text]
41. Lee S, Bacha F, Gungor N, et al. Comparison of different definitions of pediatric metabolic syndrome: relation to abdominal adiposity, insulin resistance, adiponectin, and inflammatory biomarkers. J Pediatr. 2008 Feb;152(2):177-84.[Abstract]
42. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2006 Nov;2(4):367-73.[Abstract]
43. Straczkowski M, Kowalska I. The role of skeletal muscle sphingolipids in the development of insulin resistance. Rev Diabet Stud. 2008 Spring;5(1):13-24.[Abstract][Full Text]
44. Yamamoto JM, Prado-Núñez S, Guarnizo-Poma M, et al. Association between serum transaminase levels and insulin resistance in euthyroid and non-diabetic adults. Diabetes Metab Syndr. 2020 Jan-Feb;14(1):17-21.[Abstract]
45. Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196.[Abstract][Full Text]
46. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-35.[Abstract][Full Text]
47. Zheng M, Lamb KE, Grimes C, et al. Rapid weight gain during infancy and subsequent adiposity: a systematic review and meta-analysis of evidence. Obes Rev. 2018 Mar;19(3):321-32.[Abstract][Full Text]
48. Arnesen EK, Thorisdottir B, Lamberg-Allardt C, et al. Protein intake in children and growth and risk of overweight or obesity: a systematic review and meta-analysis. Food Nutr Res. 2022;66.[Abstract][Full Text]
49. Cioana M, Deng J, Nadarajah A, et al. Prevalence of polycystic ovary syndrome in patients with pediatric type 2 diabetes: a systematic review and meta-analysis. JAMA Netw Open. 2022 Feb 1;5(2):e2147454.[Abstract][Full Text]
50. Kings College London. Onset and care of type 2 diabetes mellitus in people with a learning disability. 2022 [internet pubication].[Full Text]
51. Taggart L, Coates V, Truesdale-Kennedy M. Management and quality indicators of diabetes mellitus in people with intellectual disabilities. J Intellect Disabil Res. 2013 Dec;57(12):1152-63.[Abstract]
52. NHS England. National diabetes audit 2021-22, report 1: care processes and treatment targets, detailed analysis report. Oct 2023 [internet publication].[Full Text]
53. Ogata BN, Hayes D. Position of the Academy of Nutrition and Dietetics: nutrition guidance for healthy children ages 2 to 11 years. J Acad Nutr Diet. 2014 Aug;114(8):1257-76.[Abstract]
54. Maessen SE, Nichols M, Cutfield W, et al. High but decreasing prevalence of overweight in preschool children: encouragement for further action. BMJ. 2023 Oct 9;383:e075736.[Abstract][Full Text]
55. Mead E, Brown T, Rees K, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years. Cochrane Database Syst Rev. 2017 Jun 22;(6):CD012651.[Abstract][Full Text]
56. World Health Organization. Carbohydrate intake for adults and children: WHO guideline. Jul 2023 [internet publication].[Full Text]
57. Belsky N, Tamaroff J, Shoemaker AH. Risk Factors for progression to type 2 diabetes in a pediatric prediabetes clinic population. J Endocr Soc. 2023 Oct 9;7(11):bvad118.[Abstract][Full Text]
58. Kleber M, deSousa G, Papcke S, et al. Impaired glucose tolerance in obese white children and adolescents: three to five year follow-up in untreated patients. Exp Clin Endocrinol Diabetes. 2011 Mar;119(3):172-6.[Abstract]
59. Weiss R, Taksali SE, Tamborlane WV, et al. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care. 2005 Apr;28(4):902-9.[Abstract][Full Text]
60. RISE Consortium. Impact of insulin and metformin versus metformin alone on beta-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care. 2018 Aug;41(8):1717-25.[Abstract][Full Text]
61. Khokhar A, Umpaichitra V, Chin VL, et al. Metformin use in children and adolescents with prediabetes. Pediatr Clin North Am. 2017 Dec;64(6):1341-53.[Abstract]
62. Serbis A, Giapros V, Kotanidou EP, et al. Diagnosis, treatment and prevention of type 2 diabetes mellitus in children and adolescents. World J Diabetes. 2021 Apr 15;12(4):344-65.[Abstract][Full Text]
63. Brickman WJ, Huang J, Silverman BL, et al. Acanthosis nigricans identifies youth at high risk for metabolic abnormalities. J Pediatr. 2010 Jan;156(1):87-92.[Abstract]
64. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013 Jul;30(7):803-17.[Abstract][Full Text]
65. Leighton E, Sainsbury CA, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes Ther. 2017 Jun;8(3):475-87.[Abstract][Full Text]
66. Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018 Sep;41(9):2026-44.[Abstract][Full Text]
67. Pihoker C, Gilliam LK, Ellard S, et al; SEARCH for Diabetes in Youth Study Group. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. 2013 Oct;98(10):4055-62.[Abstract][Full Text]
68. Peixoto-Barbosa R, Reis AF, Giuffrida FMA. Update on clinical screening of maturity-onset diabetes of the young (MODY). Diabetol Metab Syndr. 2020;12:50.[Abstract][Full Text]
69. Sanyoura M, Philipson LH, Naylor R. Monogenic diabetes in children and adolescents: recognition and treatment options. Curr Diab Rep. 2018 Jun 22;18(8):58.[Abstract][Full Text]
70. Greeley SA, Naylor RN, Philipson LH, et al. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep. 2011 Dec;11(6):519-32.[Abstract][Full Text]
71. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023 Feb 1;151(2):e2022060640.[Abstract][Full Text]
72. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Screening for prediabetes and type 2 diabetes in children and adolescents: US preventive services task force recommendation statement. JAMA. 2022 Sep 13;328(10):963-7.[Abstract][Full Text]
73. Viner R, White B, Christie D. Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden. Lancet. 2017 Jun 3;389(10085):2252-60.[Abstract]
74. Simmons D, Voyle J, Rush E, et al. The New Zealand experience in peer support interventions among people with diabetes. Fam Pract. 2010 Jun;27(suppl 1):i53-61.[Abstract][Full Text]
75. Neyman A, Hannon TS, Committee on Nutrition. Low-carbohydrate diets in children and adolescents with or at risk for diabetes. Pediatrics. 2023 Oct 1;152(4):e2023063755.[Abstract][Full Text]
76. Willi SM, Martin K, Datko FM, et al. Treatment of type 2 diabetes in childhood using a very-low-calorie diet. Diabetes Care. 2004 Feb;27(2):348-53.[Abstract][Full Text]
77. Vadiveloo MK, Gardner CD, Bleich SN, et al. Ultraprocessed foods and their association with cardiometabolic health: evidence, gaps, and opportunities: a science advisory from the American Heart Association. Circulation. 2025 Sep 23;152(12):e245-63.[Abstract][Full Text]
78. Dela F, von Linstow ME, Mikines KJ, et al. Physical training may enhance beta-cell function in type 2 diabetes. Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E1024-31.[Abstract][Full Text]
79. Marwick TH, Hordern MD, Miller T, et al. Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009 Jun 30;119(25):3244-62.[Abstract][Full Text]
80. McCall A, Raj R. Exercise for prevention of obesity and diabetes in children and adolescents. Clin Sports Med. 2009 Jul;28(3):393-421.[Abstract]
81. Christie D, Strange V, Allen E, et al. Maximising engagement, motivation and long term change in a structured intensive education programme in diabetes for children, young people and their families: Child and Adolescent Structured Competencies Approach to Diabetes Education (CASCADE). BMC Pediatr. 2009 Sep 15;9:57.[Abstract][Full Text]
82. Misra A, Nigam P, Hills AP, et al. Consensus physical activity guidelines for Asian Indians. Diabetes Technol Ther. 2012 Jan;14(1):83-98.[Abstract]
83. Johnson ST, Newton AS, Chopra M, et al. In search of quality evidence for lifestyle management and glycemic control in children and adolescents with type 2 diabetes: a systematic review. BMC Pediatr. 2010 Dec 23;10:97.[Abstract][Full Text]
84. Zeitler P, Hirst K, Pyle L, et al; TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012 Jun 12;366(24):2247-56.[Abstract][Full Text]
85. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203.[Abstract][Full Text]
86. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al; Ellipse Trial Investigators. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019 Aug 15;381(7):637-46.[Abstract][Full Text]
87. Tamborlane WV, Bishai R, Geller D, et al. Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care. 2022 Aug 1;45(8):1833-40.[Abstract][Full Text]
88. Arslanian SA, Hannon T, Zeitler P, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022 Aug 4;387(5):433-43.[Abstract][Full Text]
89. Laffel LM, Danne T, Klingensmith GJ, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-81.[Abstract][Full Text]
90. Tamborlane WV, Laffel LM, Shehadeh N, et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022 May;10(5):341-50.[Abstract][Full Text]
91. Shehadeh N, Barrett T, Galassetti P, et al. Dapagliflozin or saxagliptin in pediatric type 2 diabetes. NEJM Evid. 2023 Dec;2(12):EVIDoa2300210.[Abstract][Full Text]
92. McCall AL, Lieb DC, Gianchandani R, et al. Management of individuals with diabetes at high risk for hypoglycemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2023 Feb 15;108(3):529-62.[Abstract][Full Text]
93. Medicines and Healthcare products Regulatory Agency (UK). GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued. Jun 2019 [internet publication].[Full Text]
94. World Gastroenterology Organisation and International Federation for the Surgery of Obesity and Metabolic Diseases. Obesity. 2023 [internet publication].[Full Text]
95. Poliakin L, Roberts A, Thompson KJ, et al. Outcomes of adolescents compared with young adults after bariatric surgery: an analysis of 227,671 patients using the MBSAQIP data registry. Surg Obes Relat Dis. 2020 Oct;16(10):1463-73.[Abstract]
96. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021 Aug 30;44(10):2438-44.[Abstract][Full Text]
97. Inge TH, Courcoulas AP, Jenkins TM, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016 Jan 14;374(2):113-23.[Abstract][Full Text]
98. Inge TH, Miyano G, Bean J, et al. Reversal of type 2 diabetes mellitus and improvements in cardiovascular risk factors after surgical weight loss in adolescents. Pediatrics. 2009 Jan;123(1):214-22.[Abstract]
99. Shankar RR, Zeitler P, Deeb A, et al. A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Pediatr Diabetes. 2022 Mar;23(2):173-82.[Abstract]
100. Jalaludin MY, Deeb A, Zeitler P, et al. Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatr Diabetes. 2022 Mar;23(2):183-93.[Abstract]
101. ClinicalTrials.gov. Phase 3 alogliptin pediatric study. ClinicalTrials.gov Identifier: NCT02856113. Oct 2022 [internet publication].[Full Text]
102. Cogen F, Rodriguez H, March CA, et al. Diabetes care in the school setting: a statement of the American Diabetes Association. Diabetes Care. 2024 Dec 1;47(12):2050-61.[Abstract][Full Text]
103. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract. 2022 Oct;28(10):923-1049.[Abstract][Full Text]
104. American Association of Diabetes Educators. Management of children with diabetes in the school setting. Diabetes Educ. 2019 Feb;45(1):54-9.[Abstract][Full Text]
105. Abraham MB, Karges B, Dovc K, et al. ISPAD Clinical Practice Consensus Guidelines 2022: assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2022 Dec;23(8):1322-40.[Full Text]
106. Adeyemi A, Rascati K, Strassels S. The need for oral antidiabetic treatment adherence studies in the pediatric population. Clin Ther. 2010 Jul;32(7):1306-7.[Abstract][Full Text]
107. Kawahara R, Amemiya T, Yoshino M, et al. Dropout of young non-insulin-dependent diabetics from diabetic care. Diabetes Res Clin Pract. 1994 Jul;24(3):181-5.[Abstract]
108. TODAY Study Group, TODAY Study Group. Long-term outcomes among young adults with type 2 diabetes based on durability of glycemic control: results from the TODAY Cohort Study. Diabetes Care. 2022 Nov 1;45(11):2689-97.[Abstract][Full Text]
109. Rosenbloom AL. Hyperglycemic hyperosmolar state: an emerging pediatric problem. J Pediatr. 2010 Feb;156(2):180-4.[Abstract]
110. Marx N, Federici M, Schütt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-140.[Full Text]
111. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013 Jun;36(6):1735-41.[Abstract][Full Text]
112. Bjornstad P, Drews KL, Caprio S, et al; TODAY Study Group. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021 Jul 29;385(5):416-26.[Abstract][Full Text]
113. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013 Jun;36(6):1758-64.[Abstract][Full Text]
114. Svensson M, Sundkvist G, Arnqvist HJ, et al. Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003 Oct;26(10):2903-9.[Abstract][Full Text]
115. Maahs DM, Snively BM, Bell RA, et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care. 2007 Oct;30(10):2593-8.[Abstract][Full Text]
116. National Institute of Health Care and Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. May 2023 [internet publication].[Full Text]
117. Sanz M, Ceriello A, Buysschaert M, et al. Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. Diabetes Res Clin Pract. 2018 Mar;137:231-41.[Abstract]
118. Khader YS, Dauod AS, El-Qaderi SS, et al. Periodontal status of diabetics compared with nondiabetics: a meta-analysis. J Diabetes Complications. 2006 Jan-Feb;20(1):59-68.[Abstract]
119. Shaw JE, Punjabi NM, Wilding JP, et al. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract. 2008 Jul;81(1):2-12.[Abstract]
120. Ke C, Lau E, Shah BR, et al. Excess burden of mental illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study. Ann Intern Med. 2019 Feb 5;170(3):145-54.[Abstract]
121. Betts P, Brink SJ, Swift PG, et al. Management of children with diabetes requiring surgery. Pediatr Diabetes. 2007 Aug;8(4):242-7.[Abstract]
122. Springer SC, Silverstein J, Copeland K, et al; American Academy of Pediatrics. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics. 2013 Feb;131(2):e648-64.[Abstract][Full Text]
